This guideline covers the recognition, assessment and management of coeliac disease in children, young people and adults.
This guideline includes recommendations on:
- recognising coeliac disease
- serological testing for coeliac disease
- referral of people with suspected coeliac disease
- information and support
- advice on dietary management
- non-responsive and refractory coeliac disease
- monitoring and review in people with coeliac disease
Who is it for?
- Healthcare staff who care for people with suspected or diagnosed coeliac disease
- Laboratories carrying out testing for coeliac disease
- Commissioners and providers of coeliac services
- People with coeliac disease or suspected coeliac disease, their families and carers
Is this guideline up to date?
We checked this guideline in December 2019. We found no new evidence that affects the recommendations in this guideline.
Guideline development process
This guideline updates and replaces NICE guideline CG86 (May 2009).
The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals and practitioners are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or the people using their service. It is not mandatory to apply the recommendations, and the guideline does not override the responsibility to make decisions appropriate to the circumstances of the individual, in consultation with them and their families and carers or guardian.
All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the Yellow Card Scheme.
Local commissioners and providers of healthcare have a responsibility to enable the guideline to be applied when individual professionals and people using services wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with complying with those duties.
Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.